Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 narsoplimab study in pediatric high-risk HSCT-TMA
NL-OMON59483Phase 2Recruiting
- Sponsor
- Omeros Corporation
- Start
- Oct 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of narsoplimab in transplant-associated thrombotic microangiopathy (TA-TMA), sponsored by Omeros Corporation. Primary endpoint: 100-day survival rate. Started Oct 2023; status: recruiting.
02
Drugs
narsoplimab
03
Conditions
transplant-associated thrombotic microangiopathy (TA-TMA)
Beyond the preview
Go deeper on NL-OMON59483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59483.